PPV Vaccine — Competitive Intelligence Brief

PPV Vaccine (PPV Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polysaccharide vaccine. Area: Immunology / Infectious Disease.

marketed Polysaccharide vaccine Streptococcus pneumoniae capsular polysaccharides Immunology / Infectious Disease Biologic

Target snapshot

PPV Vaccine (PPV Vaccine) — Fakultas Kedokteran Universitas Indonesia. PPV vaccine stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens, providing protection against Streptococcus pneumoniae infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PPV Vaccine TARGET	PPV Vaccine	Fakultas Kedokteran Universitas Indonesia	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
PPV23 alone	PPV23 alone	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
pneumococcal conjugate 13 valent vaccine	pneumococcal conjugate 13 valent vaccine	University of Siena	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (13 serotypes)
Influenza vaccination with PCV13	Influenza vaccination with PCV13	Korea University Guro Hospital	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Investigational 23-valent PPV	Investigational 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
ProDiax-23 (PPSV23)	ProDiax-23 (PPSV23)	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Polysaccharide vaccine class)

1. Korea University Guro Hospital · 2 drugs in this class
2. Celgene · 1 drug in this class
3. Fakultas Kedokteran Universitas Indonesia · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. Hualan Biological Engineering, Inc. · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. University Hospital, Montpellier · 1 drug in this class
8. University of Minnesota · 1 drug in this class
9. Astellas Pharma Inc · 1 drug in this class
10. Walvax Biotechnology Co., Ltd. · 1 drug in this class